Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors

Neurology

Volumn 78, Issue 13, 2012, Pages 957-963

  Pariente, A ^a,b,c   Fourrier Reglat A ^a,b   Bazin, F ^a   Ducruet, T ^c   Dartigues, J F ^a,b,d   Dragomir, A ^c   Perreault, S ^c   Moore, N ^a,b   Moride, Y ^a,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

AGED; ARTICLE; CANADA; CONTROLLED STUDY; DEATH; DEMENTIA; FEMALE; HUMAN; INSTITUTIONALIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; THERAPY EFFECT; TREATMENT GAP; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 84860789019     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31824d5773     Document Type: Article

References (39)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
2. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005;366: 2112-2117. (Pubitemid 41797645)
3. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts: Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S10-S15. (Pubitemid 30390599)
4. Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007;120: 388-397. (Pubitemid 46627453)
5. Bond J, Stave C, Sganga A, O'Connell B, Stanley RL. Inequalities in dementia care across Europe: Key findings of the Facing Dementia Survey. Int J Clin Pract 2005; (suppl):8-14. (Pubitemid 40333120)
6. Gruber-Baldini AL, Stuart B, Zuckerman IH, Simoni-Wastila L, Miller R. Treatment of dementia in communitydwelling and institutionalized medicare beneficiaries. J Am Geriatr Soc 2007;55:1508-1516. (Pubitemid 47508513)
7. Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007;55:1517-1523. (Pubitemid 47508507)
8. Pariente A, Helmer C, Fourrier A, Moore N, Dartigues JF. Prevalence of drug treatment in subjects with Alzheimer's disease in Europe. Pharmacoepidemiol Drug Saf 2008;17: 655-660.
9. Feldman HH, Pirttila T, Dartigues JF, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry 2009;24:479-488.
10. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006:CD005593.
11. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: A meta-analysis. CMAJ 2003;169:557-564. (Pubitemid 37174596)
12. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006:CD001747.
13. Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, DeKosky ST. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 2005;53:83-87. (Pubitemid 41647636)
14. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 2008;148:379-397. (Pubitemid 351665469)
15. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis. JAMA 2003;289:210-216. (Pubitemid 36068709)
16. US Food and Drug Administration. Peripheral and Central Nervous System Drugs Advisory Committee Meeting. Rockville, MD: Department of Health and Human Services, Public Health Service; 1989.
17. European Medicine Evaluation Agency (EMEA). Note for Guidance on Medicinal Products in the Treatment of Alzheimer's Disease. London: EMEA; 1997.
18. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials. BMJ 2005;331:321-327.
19. Loveman E. Appraisal Consultation Document: Alzheimer's Disease: Donepezil, Rivastigmine, Galantamine and Memantine (review). London: National Institute for Clinical Excellence; 2005.
20. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: A randomized crossover study. Arch Neurol 2000;57:94-99. (Pubitemid 30027636)
21. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil Study Group. Neurology 1998;50:136-145.
22. Amuah J, Hogan D, Eliasziw M, et al. Persistence of cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf 2010;19:670-679.
23. Pariente A, Pinet M, Moride Y, Merlière Y, Moore N, Fourrier-Réglat A. Factors associated with persistence of anti-Alzheimer drugs in France. Pharmacoepidemiol Drug Saf 2010;19:680-686.
24. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349: 151-154. (Pubitemid 27039193)
25. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: The Rotterdam Study. Diabetologia 1996;39: 1392-1397. (Pubitemid 26356072)
26. Raffaitin C, Gin H, Empana JP, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: The Three-City Study. Diabetes Care 2009;32: 169-174.
27. Gamaldo A, Moghekar A, Kilada S, Resnick SM, Zonderman AB, O'Brien R. Effect of a clinical stroke on the risk of dementia in a prospective cohort. Neurology 2006;67: 1363-1369. (Pubitemid 44632058)
28. Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer's disease: Results from EURODEM pooled analyses: EURODEM Incidence Research Group and Work Groups European Studies of Dementia. Neurology 1999;52:78-84. (Pubitemid 29044403)
29. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: The Hisayama Study. Neurology 1995;45:1161-1168.
30. AD2000 Collaborative Group, Bentham P, Gray R, et al. Aspirin in Alzheimer's disease (AD2000): A randomised open-label trial. Lancet Neurol 2008;7:41-49.
31. Nilsson SE, Johansson B, Takkinen S, et al. Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged > or =80 years. Eur J Clin Pharmacol 2003;59:313-319. (Pubitemid 37100350)
32. Hayden KM, Zandi PP, Khachaturian AS, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache County Study. Neurology 2007;69:275-282. (Pubitemid 47205690)
33. Szekely CA, Breitner JC, Fitzpatrick AL, et al. NSAID use and dementia risk in the Cardiovascular Health Study: Role of APOE and NSAID type. Neurology 2008;70:17-24.
34. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: The Cache County Study. Arch Neurol 2006;63:686-692.
35. Ohrui T, Tomita N, Sato-Nakagawa T, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004;63:1324-1325. (Pubitemid 39350046)
36. Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:71-77. (Pubitemid 44015228)
37. Scott HD, Laake K. Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev 2001: CD003160.
38. Winblad B, Jelic V, Kershaw P, Amatniek J. Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials. Drugs Aging 2007; 24:57-61. (Pubitemid 46148081)
39. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. BMJ 2010; 340:b5465.